UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

(Amendment No. 12)

Under the Securities Exchange Act of 1934

CLARUS CORPORATION

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

18270P109

(CUSIP Number)

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

May 25, 2022

(Date of Event which requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨

This Amendment No. 12 amends the Statement of Beneficial Ownership on Schedule 13D originally filed with the Securities and Exchange Commission on April 12, 2002, as amended by Amendment No. 1 filed on June 6, 2002, as amended by Amendment No. 2 filed on October 29, 2002, as amended by Amendment No. 3 filed on April 17, 2003, as amended by Amendment No. 4 filed on August 20, 2008, as amended by Amendment No. 5 filed on December 9, 2008, as amended by Amendment No. 6 filed on January 5, 2009, as amended by Amendment No. 7 filed on May 14, 2010, as amended by Amendment No. 8 filed on June 4, 2010, as amended by Amendment No. 9 filed on February 28, 2012, as amended by Amendment No. 10 filed on October 18, 2013, and as amended by Amendment No. 11 filed on January 31, 2019 (collectively, the “Schedule 13D”) by the Reporting Persons (as defined in the Schedule 13D) with respect to the shares of common stock, par value $0.0001 per share (the “Common Stock”), of Clarus Corporation (the “Company”), a Delaware corporation, whose principal executive office is located at: 2084 East 3900 South, Salt Lake City, Utah 84124. Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the Schedule 13D. Unless specifically amended hereby, the disclosures set forth in the Schedule 13D shall remain unchanged.

Item 4. Purpose of Transaction.

Item 4 of the Schedule 13D is hereby amended to include the following:

This Schedule 13D is filed by the Reporting Persons to report a disposition of shares of Common Stock which decreases their beneficial ownership (as such term is defined under Rule 13d-3 under the Exchange Act of 1934, as amended) of the Common Stock of the Company by more than 1% from the amounts previously reported on the Schedule 13D previously filed by the Reporting Persons with the Commission on filed on January 31, 2019.

The Reporting Persons may review their investment in the Company on a continuing basis, and to the extent permitted by law, may engage in discussions with other stockholders and/or with management and other members of the Board of Directors of the Company concerning the business, operations or future plans of the Company. Depending on various factors including, without limitation, the Company’s financial position, the price levels of the Common Stock, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may, subject to their legal obligations, in the future take such actions with respect to their investment in the Company as they deem appropriate including, without limitation, purchasing additional shares of Common Stock, selling shares of Common Stock, engaging in short selling of or any hedging or similar transaction with respect to the Common Stock, taking any other action with respect to the Company or any of its securities in any manner permitted by law or changing their intention with respect to any and all matters referred to in paragraphs (a) through (j) of Item 4.

Item 5. Interest in Securities of the Issuer.

Item 5 of the Schedule 13D is hereby amended and restated in its entirety to read as follows:

(a), (b) and (c). As of the date of this Schedule 13D, Mr. Kanders may be deemed to be the beneficial owner (as that term is defined under Rule 13d-3 under the Exchange Act of 1934, as amended) of, and has the sole power to direct the vote and disposition of 6,051,235 shares of Common Stock, constituting approximately 16.0% of the outstanding shares of Common Stock, which is comprised of: (i) 3,642,005 shares of Common Stock owned directly by Mr. Kanders; (ii) 1,528,464 shares of Common Stock held by Holdings, of which Mr. Kanders is a majority member and a trustee of the manager of Holdings; (iii) options to purchase an aggregate of 635,333 shares of Common Stock which were previously granted under the Company’s 2015 Stock Incentive Plan and are presently exercisable and exercisable within 60 days of the date of this Schedule 13D; (iv) 10,851 shares of Common Stock that Mr. Kanders may be deemed to beneficially own as UTMA custodian for his children; (v) 125,222 shares of Common Stock held by Mr. Kanders’ spouse in a UTA Trust Account of which Mr. Kanders is the sole trustee; (vi) 8,916 shares of Common Stock that Mr. Kanders may be deemed to beneficially own as joint tenancy with rights of survivorship; and (vii) 100,444 shares of Common Stock that are beneficially owned by Mr. Kanders’ spouse

The amount reported above as being beneficially owned by Mr. Kanders excludes (i) options to purchase 270,666 shares of Common Stock which were previously granted under the Company’s 2015 Stock Incentive Plan and are not presently exercisable and not exercisable within 60 days of the date of this Schedule 13D; (ii) stock award of 233,333 shares of restricted Common Stock which were previously granted under the Company’s 2015 Stock Incentive Plan of which (A) 116,667 shares of Common Stock shall vest on January 28, 2023; and (B) 116,666 shares of Common Stock shall vest on January 28, 2024, (iii) a stock award of 500,000 shares of restricted Common Stock which were previously granted under the Company’s 2015 Stock Incentive Plan and all of which shall vest if on or before May 28, 2024, the Fair Market Value (as defined in the 2015 Stock Incentive Plan) of the Company’s Common Stock shall have equaled or exceeded $35.00 per share for twenty consecutive trading days; and (iv) a stock award of 500,000 shares of restricted Common Stock which were previously granted under the Company’s 2015 Stock Incentive Plan and all of which shall vest if on or before March 4, 2032, the Fair Market Value (as defined in the 2015 Stock Incentive Plan) of the Common Stock shall have equaled or exceeded $50.00 per share for twenty consecutive trading days.

The percentage of shares of Common Stock reported as being beneficially owned by Mr. Kanders is based upon 37,859,442 shares of Common Stock outstanding as of the date of this Schedule 13D, which includes: (i) 37,224,109 shares of Common Stock outstanding as of May 4, 2022, as set forth in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed with the Commission on May 9, 2022; and (ii) options to purchase an aggregate of 635,333 shares of Common Stock which were previously granted under the Company’s 2015 Stock Incentive Plan and that are presently exercisable and exercisable within 60 days of the date of this Schedule 13D.

The Reporting Persons have engaged in the following transactions involving shares of Common Stock during the last 60 days.

(1) The price reported is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $20.11 to $21.92. The Reporting Persons undertake to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3) and (4).

(2) The price reported is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $21.21 to $22.21.

(3) The price reported is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $20.50 to $23.04.

(4) The price reported is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $21.45 to $22.40.

(d) and (e). Not Applicable.

SIGNATURE

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: June 2, 2022